Inclisiran in Patients with Elevated LDL Cholesterol

This phase 3 trial evaluated inclisiran — a small interfering RNA (siRNA) targeting hepatic PCSK9 mRNA — in 3,178 patients with elevated LDL-C despite maximum-tolerated statin therapy. Inclisiran is administered subcutaneously at day 1, day 90, then every 6 months.

At 17 months, inclisiran reduced LDL-C by approximately 50% compared with placebo — comparable to monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab) in degree of LDL-C reduction. The reduction was sustained throughout the dosing interval, demonstrating that the twice-yearly regimen maintains persistent LDL-C lowering. Injection-site reactions were more frequent with inclisiran but were mild and did not cause significant discontinuation.

The clinical significance of inclisiran is primarily its dosing convenience. Monoclonal PCSK9 inhibitors require biweekly or monthly injections; inclisiran requires only two injections per year after the first year. Adherence to injectable therapies falls sharply with dosing frequency, and the twice-yearly regimen could substantially improve long-term adherence in eligible patients.

At the time of publication, cardiovascular outcomes data were not yet available. The ORION-4 trial was designed to provide those data. Until outcomes data confirmed clinical event reduction, inclisiran’s place was established by its LDL-C lowering effect and the extrapolation from the established LDL-C/outcomes relationship.

We rate the evidence strong for lipid-lowering effect. A well-executed phase 3 trial confirming durable 50% LDL-C reduction with twice-yearly inclisiran — with clinical significance contingent on forthcoming outcomes data.